Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The Carlyle Group (NASDAQ:CG) Cut to Sell at StockNews.com
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
BioPharma Dive1d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Carlyle's Savino Expects IPOs to Increase in 2025
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
The Search For 7% Investment Grade Yields, Part 2: Carlyle And Its Baby Bond
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...
Carlyle Acquires Highway-Roop Auto Parts Platform in India
Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...